Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biorestorative Therapies Inc (NQ: BRTX )

2.065 -0.065 (-3.05%)
Streaming Delayed Price Updated: 12:50 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biorestorative Therapies Inc

< Previous 1 2 3 4 Next >
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions... 
Via Benzinga
EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into a supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics.  
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying – the “smart money” – can also be an indicator to evaluate... 
Via Benzinga
Over $4M Bet On Yellow Corp? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher on Friday, also recording gains for the week. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. 
Via Benzinga
$5.7M Bet On This Tech Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher on Tuesday, recording gains for the 12th straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Why Metropolitan Bank Holding Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) jumped 69% to $22.59 after the company announced it reached a settlement with the SEC. 
Via Benzinga
BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered
BioRestorative Therapies Inc (NASDAQ: BRTX) shares are trading lower by 17.13% to $2.95 Tuesday morning after the company announced a $2.1 million registered direct offe 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumb 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar disc disease,... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise. 
Via Benzinga
EXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain Trial
BioRestorative Therapies Inc (NASDAQ: BRTX) announced that the final subject in its BRTX-100 Phase 2 trial safety cohort has been dosed. 
Via Benzinga
EXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell Processing
BioRestorative Therapies, Inc (NASDAQ: BRTX), bagged a license from the New York State Department of Health to act as a tissue bank for processing  
Via Benzinga
A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate
Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc (NASDAQ: BRTX) in... 
Via Benzinga
EXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese Patent
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to its metabolic ThermoStem... 
Via Benzinga
EXCLUSIVE: BioRestorative Therapies & Northwell Health Ink Trial Pact For Chronic Lower Back Pain Study
BioRestorative Therapies Inc (NASDAQ: BRTX) has signed a clinical trial agreement with Northwell Health and Northwell's Feinstein Institutes for Medical Research to participate in the company's Phase 2... 
Via Benzinga
EXCLUSIVE: BioRestorative Concludes Enrollment For Safety Run-In Component Of Cell Therapy Study For Chronic Lower Back Pain
BioRestorative Therapies Inc (NASDAQ: BRTX) has completed enrollment for the safety run-in component of its Phase 2 study of BRTX-100 targeting patients suffering from chronic lumbar disc disease... 
Via Benzinga
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.